{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:04:49Z","timestamp":1783998289090,"version":"3.55.0"},"reference-count":9,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>The 2024 British Thoracic Society\/ National Institute for Health and Care Excellence\/ Scottish Intercollegiate Guidelines Network asthma guidelines recommend anti-inflammatory reliever (AIR)-based management, providing opportunity to reduce short-acting beta agonist (SABA) over-use. Many English regions also publish local guidelines. Analysis of 34 regional guidelines enabled grouping into three categories: SABA-first, inhaled corticosteroid (ICS) plus SABA and AIR (as-needed AIR), based on recommended initial treatment. Interrupted time series analysis using publicly available data demonstrated that AIR guideline publication resulted in the greatest decline in SABA prescribing, expressed as the proportion of all ICS-containing and SABA inhaler prescriptions (AIR: \u22120.26% (SD 0.09%) per month; SABA-first: \u22120.1% (SD 0.03%) per month, p=0.001 vs AIR; and ICS plus SABA: \u22120.16% (SD 0.06%) per month, p=0.004, vs AIR). Therefore, regional guidelines do affect local prescribing practice and alignment with the latest national recommendations could improve asthma prescribing and resulting patient outcomes.<\/jats:p>","DOI":"10.1136\/thorax-2025-223239","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T17:20:19Z","timestamp":1756833619000},"page":"853-857","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of regional asthma guidelines on SABA prescribing patterns across England: an interrupted time series analysis"],"prefix":"10.1136","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0925-7772","authenticated-orcid":false,"given":"Dominic L","family":"Sykes","sequence":"first","affiliation":[{"name":"Respiratory Research Group, Hull York Medical School, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Clarkson","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, Hull University Teaching Hospitals NHS Trust, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Negbenebor","sequence":"additional","affiliation":[{"name":"Hull York Medical School, Hull, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Cummings","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, Hull University Teaching Hospitals NHS Trust, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoaib","family":"Faruqi","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, Hull University Teaching Hospitals NHS Trust, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Lau","sequence":"additional","affiliation":[{"name":"Hull York Medical School, Hull, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjanlal","family":"Ahilal","sequence":"additional","affiliation":[{"name":"Hull York Medical School, Hull, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-0258","authenticated-orcid":false,"given":"Michael G","family":"Crooks","sequence":"additional","affiliation":[{"name":"Respiratory Research Group, Hull York Medical School, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2026071304500816000_80.11.853.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.047"},{"key":"2026071304500816000_80.11.853.2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01872-2019","article-title":"Overuse of short-acting \u03b22-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme","volume":"55","author":"Nwaru","year":"2020","journal-title":"Eur Respir J"},{"key":"2026071304500816000_80.11.853.3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01046-2019","article-title":"GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents","volume":"53","author":"Reddel","year":"2019","journal-title":"Eur Respiratory Soc"},{"key":"2026071304500816000_80.11.853.4","unstructured":"Busse R , Klazinga N , Panteli D , et al . Improving healthcare quality in Europe. 2019."},{"key":"2026071304500816000_80.11.853.5","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.jaip.2023.04.041","article-title":"Patterns of Asthma Medication Use in New Zealand After Publication of National Asthma Guidelines","volume":"11","author":"Hatter","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026071304500816000_80.11.853.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-024-00379-6","article-title":"Can we measure whether asthma guidelines lead to improved care?","volume":"34","author":"Tan","year":"2024","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026071304500816000_80.11.853.7","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00685-2022","article-title":"Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site","volume":"9","author":"Crooks","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026071304500816000_80.11.853.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901963"},{"key":"2026071304500816000_80.11.853.9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","article-title":"Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial","volume":"394","author":"Hardy","year":"2019","journal-title":"The Lancet"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:26:56Z","timestamp":1783996016000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":9,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/thorax-2025-223239"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223239","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}